Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Declining circulating tumor cell (CTC) count in treated patients.

Data 100

Data Research and Development Clinical Trials Therapy 100

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

DECEMBER 27, 2019

A Windsor, Ontario-based company Audacia Bioscience is especially focussed on three patented technologies that deliver consumer and patient insights to the industry to close the knowledge gaps in the supply chain. Clinical trials are medical research projects involving human participants.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Cannabis Law Report

JULY 28, 2021

The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company. . – July 28, 2021) – PharmaDrug Inc.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

MAY 29, 2022

is a Canadian company that researches, develops and grows psilocybin-producing mushrooms and functional mushrooms. Businesses have been recently receiving approval from Health Canada to farm psychedelic mushrooms, make psilocybin and sell the compound to drug-makers, or to doctors to give to patients. Optimi Health Corp.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Veriheal

NOVEMBER 21, 2023

Quemarr Moatamedi School: University of Montana Major/Program: Linguistics and Anthropology Innovation: Emulsion-Based Edibles: Harnessing Anti-Diabetic Cannabinoids in Diabetes Management. Scientific research supports the potential of cannabinoids in regulating blood sugar levels, weight management, and addressing diabetic neuropathy.

Research and Development 106

Research and Development Consumption Education Data 106

United Patients Group

JANUARY 4, 2024

As we move forward into 2024 and beyond, the sector offers diverse paths beyond direct patient care. The growth stems from rising healthcare demand, facility expansion, and the imperative for efficient administration to maintain quality patient care. Adverse drug events (ADEs) affect approximately 7 per 100 hospitalized patients.

Research and Development 52

Research and Development Patients Data Policy 52

Veriheal

JANUARY 10, 2022

Enter cannabis, the plant medicine that is quickly becoming the remedy of choice for patients who have been diagnosed with breast cancer according to a recently conducted survey that was published in the journal Cancer. Breast Cancer Patients and Medical Cannabis. More cancer patients in the U.S. Over 600 Study Participants .

Patients 98

Patients Treatment Medicine Consumption 98

Cannabis Law Report

JANUARY 6, 2022

Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. By Brett Mulligan.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

DECEMBER 26, 2021

In furtherance of its program, the Company filed US Provisional Patent Application No. “Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. US Provisional Patent Filed. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

SpeedWeed

MARCH 14, 2021

Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.

Data 52

Data Research and Development Marijuana Collective 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. The program will be offered for free to Québec physicians and is made possible by an unrestricted educational grant from Spectrum Therapeutics.

Programs 108

Programs Research and Development Education Treatment 108

MMJ Recs

MARCH 16, 2024

Economic Growth and Job Creation of the medical marijuana industry The medical cannabis sector serves as a catalyst for economic expansion and workforce development in regions where it’s legalized. Moreover, ensuring product quality and safety throughout the supply chain is paramount to maintain patient trust and regulatory compliance.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. A 2019 study found that 76% of patients in the U.S. fill an opioid prescription after having surgery compared to just 11% of Swedish patients.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Cannabis Law Report

JANUARY 31, 2022

(TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 1, 2021

The bill, now signed into law, includes numerous patient-focused updates to the Pennsylvania Medical Marijuana Program , the majority of which became effective immediately upon the Governor’s signing. of House members.

Programs 85

Programs Supply Chain Research and Development Marijuana 85

Cannabis Law Report

NOVEMBER 29, 2021

Medical marijuana has received more attention from legislators, scientists, researchers, clinicians, and the general public than any other topic. . Updated Researches On The Use Of Medical Marijuana . As part of a prior study, these claims used data from states that legalized recreational marijuana usage by the middle of 2018.

Legalization 52

Legalization Research and Development Decriminalization Marijuana 52

Cannabis Law Report

SEPTEMBER 23, 2021

BIMA was an Open-label safety, tolerability and proof-of-concept study to investigate the role of MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD). This data will assist Awakn’s progress by enabling a better design and more efficient execution of its clinical program.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Veriheal

AUGUST 31, 2021

This year, we are happy to announce we are expanding our scholarship program and awarding $20,0000 in scholarships to 20 winners. . Major/Program: Business Management with a Minor in Cannabis Studies. Major/Program: Art. Major/Program: Business Administration. Major/Program: Nursing. Matthew Aaron Vogel .

Research and Development 116

Research and Development Supply Chain Programs Education 116

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

The Cannigma

NOVEMBER 23, 2021

And for the most part, patients are undertaking this journey alone and often with little guidance. There is also a lack of access to healthcare professionals, and experts in the field, to guide patients through this complicated process. Tell us a bit more about the interview, what did you two talk about?

Data 52

Data Patients Access Wellness and Beauty 52

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Data Bridge sees strong psychedelics growth.

Research and Development 105

Research and Development Data Conditions Therapy 105

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. So, why did this educational gap develop? Unfortunately, this did not occur.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

AUGUST 14, 2019

Let’s take a closer look at five key ways big data and technology are directly impacting the industry. Big Data Streamlines the Marijuana Regulatory Process and Helps Close the Scientific Research Gap. Big Data Improves Distribution in the Marijuana Industry. Source: [link]. Global Cannabis Applications Corp.

Data 45

Data Research and Development Marijuana Collective 45

Sensi Seeds

DECEMBER 10, 2018

At the same time, research on medical cannabis over the past two decades has not ceased to increase and provide evidence of the plant’s medical value. As a result, medical and scientific research has been highly constrained for many decades. Exponential Increase in Cannabis Research: Trends.

Medicine 81

Medicine Research and Development Data Policy 81

SpeedWeed

MAY 28, 2021

New Hampshire will now be expanding the pool of patients eligible to receive medical cannabis, thanks to a newly signed bill, HB 89. Under this new law, physicians will be allowed to authorize patients who have moderate or severe insomnia to use medical cannabis. The ratio they used was 30 percent CBD and 1.5 HB 89 and Beyond.

Programs 52

Programs Research and Development Patients Safety 52

NORML

MARCH 7, 2019

Also introduced was The Marijuana Data Collection Act of 2019 , which would study the effects of state legalized medicinal and non-medicinal marijuana programs from a variety of perspectives, including state revenues, public health, substance abuse and opioids, criminal justice, and employment.

Legislation 249

Legislation Marijuana Policy Research and Development 249

Healer

NOVEMBER 15, 2023

Let’s start by taking a look at the new data and what it means. First, it’s important to point out that I usually wait until new data makes its way through the scientific peer-review process and is published in a journal before giving it much time and energy. During that time, 2,958 (1.9%) developed heart failure.

Data 126

Data Topical Research and Development Conditions 126

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Program between St. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .

Research and Development 117

Research and Development Education Agriculture Patients 117

The Cannigma

AUGUST 5, 2022

But today, thanks to a combination of changing laws and attitudes and a building consensus of scientific research, there’s another, perhaps unexpected option – ketamine. A 2022 study of 22 patients with treatment-resistant depression found a 42% reduction in depressive symptoms with ketamine infusions. What is ketamine treatment?

Treatment 138

Treatment Research and Development Therapy Digestion 138

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek’s Seed to Patient business model combines cutting edge cultivation expertise and world class manufacturing practices to deliver high quality medicinal cannabis oil formulations and medicinal strains of dried flowers at a significantly lower cost to patients and retailers.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

The Cannigma

MARCH 2, 2021

This issue is compounded when veterans do, on rare occasions, ask their doctors about medical marijuana, only to be treated as if they are mentally unstable or receive no specific health information at all,” the researchers found. This directly conflicts with past research claiming marijuana increases PTSD symptom severity.”.

Research and Development 143

Research and Development Treatment Chronic Pain Sleep 143

PrestoDoctor

SEPTEMBER 6, 2023

It has been a go-to option for healthcare professionals seeking to manage pain effectively for their patients. This has led many patients to explore cannabis as a potential substitute for prescription codeine. Additionally, common side effects such as drowsiness, constipation, and respiratory depression can be burdensome for patients.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. The program will be offered for free to Québec physicians and is made possible by an unrestricted educational grant from Spectrum Therapeutics.

Programs 40

Programs Research and Development Education Treatment 40